Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2004-01-15
2008-07-01
Coleman, Brenda L. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S278000
Reexamination Certificate
active
07393854
ABSTRACT:
The invention relates to thienopyrimidinediones of formula (I):wherein:R1, R2, Q are as defined in the specification, and Ar and Ar2are selected from certain aromatic ring systems which may be optionally substituted, as defined in the specification.Processes for the preparation of compounds of formula (I), pharmaceutical compositions containing them and their use in therapy are also described and claimed.
REFERENCES:
patent: 6180635 (2001-01-01), Cheshire et al.
patent: 6232320 (2001-05-01), Stewart et al.
patent: 6300334 (2001-10-01), Bantick et al.
patent: 6342502 (2002-01-01), Cheshire et al.
patent: 7064126 (2006-06-01), Cooper et al.
patent: 2004/0171623 (2004-09-01), Reynolds et al.
patent: 2004/0254198 (2004-12-01), Reynolds et al.
patent: 2006/0052400 (2006-03-01), Guile
patent: WO 98/54190 (1998-12-01), None
patent: WO 99/29695 (1999-06-01), None
patent: WO 00/12514 (2000-03-01), None
patent: WO 03/008422 (2003-01-01), None
patent: WO 03/011868 (2003-02-01), None
patent: WO 2004/065393 (2004-08-01), None
patent: WO 2004/065394 (2004-08-01), None
“New Drugs for Asthma, Allergy and COPD,” Prog. Respir. Res. Basel, Karger, 2001, vol. 31, pp. 212-216.
BestHealth entry for ARDS (adult respiratory distress syndrome) <http://www.wfubmc.edu/besthealth/ency/article/000103prv.htm>.
MDAdvice.com entry for Asthma <http://www.mdadvice.com/topics/asthma/info/1.htm> downloaded from the Internet Mar. 5, 2003.
AllRefer.com Health entry for Chronic Obstructive Pulmonary Disease <<http://health.allrefer.com/health/chronic-obstructive-pulmonary-disease-prevention.html>> downloaded from the Internet Aug. 23, 2004.
Yamaguchi et al., “Novel Antiasthmatic Agents with Dual Activities of Thromboxane A2Synthetase Inhibition and Bronchodilation. V.1)Thienopyridazinone Derivatives”,Chem. Pharm. Bull. 43(2):236-240 (1995).
Gupta et al., “Tacrolimus: a review of its use for the management of dermatoses”,J. Eur. Acad. Dermatol. Venereal. 16:100-114 (2002).
Meagher et al., “Atopic dermatitis: Review of immunopathogenesis and advances in immunosuppressive therapy”,Australas. J. Derm. 43:247-254 (2002).
Perrett et al., “Cyclosporin in childhood psoriasis”,Journal of Dermatological Treatment14:113-118 (2003).
Tan et al., “Psoriasis”,Drugs of Today34(7):641-647 (1998).
Thestrup-Pedersen, “Tacrolimus treatment of atopic eczema/dermatitis syndrome”,Curr Opin Allergy Clin Immunol3:359-362 (2003).
Wolff et al., “Pimecrolimus for the treatment of inflammatory skin disease”,Expert Opin. Pharmacother. 5:643-655 (2004).
Yamamoto et al., “Topical tacrolimus: an effective therapy for facial psoriasis”,Eur J Dermatol13:471-473 (2003).
Yu et al., “Refractory atopic dermatitis treated with low dose cyclosporin”,Annals of Allergy, Asthma&Immunology89:127-131 (2002).
Guile Simon David
Ingall Anthony Howard
AstraZeneca AB
Coleman Brenda L.
Moore Susanna
LandOfFree
Thienopyrimidinedinones and their use in modulation of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Thienopyrimidinedinones and their use in modulation of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Thienopyrimidinedinones and their use in modulation of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3972992